Navigation Links
Pharmalink AB Raises SEK 35 Million Through Share Issue
Date:1/4/2012

STOCKHOLM, January 4, 2012 /PRNewswire/ --

Pharmalink AB, today announces it has raised SEK 35 million through a rights issue of new shares to the Company's existing shareholders, including Industrifonden.

The new funds will be used to further advance Nefecon® and Busulipo™, Pharmalink's two lead product candidates. Nefecon is the first pharmaceutical product especially developed for patients with IgA nephropathy, the most common form of primary glomerulonephritis and a cause of end-stage renal disease requiring treatment with dialysis or transplantation. Nefecon has shown positive results in an open-labeled Phase II trial evaluating safety and efficacy and Pharmalink is currently focusing on preparing pivotal clinical trials.

Busulipo is being developed to provide a best-in-class conditioning agent for use priorto hematopoietic stem cell transplantation (HSCT), also often known as bone marrow transplantation. Busulipo has successfully undergone Phase II clinical trials and extensive data on efficacy, safety and pharmacokinetics compare positively with historical controls. Pharmalink is currently preparing for late stage clinical trials and for the registration and introduction of Busulipo into key global markets.

Pharmalink's Managing Director Johan Häggblad said, "Pharmalink's ability to raise capital in the current difficult economic climate reflects the potential of our product pipeline and the confidence our shareholders have in our Company and strategy. Our two main product candidates have shown very promising results and this new funding will support their further progress towards becoming new medicines for important indications."

Lennart Hansson, Investment Director at Industrifonden and member of the Pharmalink Board said: "As part of Industrifonden's investment strategy, we are seeking to direct more significant capital to work in those companies we believe will deliver major successes. Pharmalink is very much in that category. The Company has shown the quality of its drug development capabilities through successful outlicensing and, in Busulipo and Nefecon, has product candidates with the potential to generate great value for investors. We very much look forward to Pharmalink continuing its work in turning these Swedish medical innovations into products that can make a real difference to patients."

About Pharmalink

Pharmalink is a Swedish specialty pharma company developing high value products for niche indications. Pharmalink draws on its extensive experience of pharmaceutical product development and the excellence of medical science in Sweden to identify and progress products that address significant unmet medical needs. Pharmalink has introduced more than 15 pharmaceutical products to the market. Using a repurposing and reformulation strategy, Pharmalink minimizes the risk of product development. The Company's strategy is to apply its expertise to drive drug development and commercialize with partners. Pharmalink currently has two clinical phase projects under development, Nefecon® and Busulipo™, and is actively in-licensing promising new projects to add to its pipeline. Visit http://www.pharmalink.se for further information.

For further information, please contact:

Pharmalink AB:
Johan Häggblad, Managing Director, +46(0)70-668-0644
Email: johan.haggblad@pharmalink.se
http://www.pharmalink.se

Citigate Dewe Rogerson:
Chris Gardner/Nina Enegren, +44-207-638-9571



'/>"/>
SOURCE Pharmalink
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmalink AB Receives US Orphan Drug Designation for Nefecon(R) (PL-56)
2. Grifols Agrees to Acquire Intellectual Property for Treatment of Post-Polio Syndrome From Pharmalink AB
3. Pharmalink AB Receives Patent for Nefecon(R) Principle
4. MacuCLEAR, Inc. Raises More Than $1M in Financing and Enters into Strategic Pacific Rim Partnership
5. Cohera Medical Raises Over $25 Million in Series C Round
6. ImmusanT Raises $20 Million in Series A Financing to Advance Immunotherapeutic and Diagnostic for Celiac Disease
7. arGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B Round
8. Vista Partners Updates Coverage on Cellmid Limited; Raises Target Price to AUD $0.12
9. Bayer Virtual Walk for Hemophilia Raises Awareness and Funds for People With Bleeding Disorders
10. NxStage Reports Record Third Quarter 2011 Financial Results and Raises Revenue Guidance For 2011
11. FRC Praises House Committee for Holding Hearing on Conscience-Violating Obamacare Contraceptive Mandate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... Sept. 7, 2017  For nearly two decades, New Life Agency has ... Reproduction Insurance industry. Today, New Life Agency announces a powerful three-way partnership ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical ... Suicidal Ideation and Behavior (ASIB), has been granted Fast Track ... sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine ... a pivotal trial of this sequential therapy targeting patients who ... 1 ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... ... setbacks, a senior finds a new lease on life with assistance from CreditAssociates. ... people resolve their problem with unsecured debt. The senior is one of the ...
(Date:9/22/2017)... , ... September 22, 2017 , ... ... on the fallacy of an obligatory tithe, and the freedom experienced when breaking ... the creation of published author, Lysa M. Harrison. , Published by Christian Faith ...
(Date:9/22/2017)... ... ... “Fruit of the Spirit: “Love””: a delightful adventure of two friends who ... the Spirit: “Love”” is the creation of published author, Halimah Jones, who was born ... is an avid writer, her inspiration for “Fruit of the Spirit: “Love”” blossomed from ...
(Date:9/21/2017)... Aliso Viejo, CA (PRWEB) , ... September 21, 2017 , ... ... never been so fun and easy to do. Users can select from up to ... more all with a click of a mouse all within Final Cut Pro ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional Communication:, Keeping Up ... , In the competitive world of drug and device marketing and promotion, drug ... FDA rules. , The FDA has issued two draft guidances that are the ...
Breaking Medicine News(10 mins):